Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Astellas promotes John Demaree

Astellas promotes John Demaree Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

Medivation softens on Sanofi takeover and opens its books

Medivation softens on Sanofi takeover and opens its books The main prize at present for Sanofi is the fast-growing prostate cancer drug Xtandi (enzalutamide), which made $1.9bn in sales last year, and which Medivation is attempting to move

Sanofi moves to replace Medivation board

Sanofi moves to replace Medivation board Sanofi is seeking to remove and replace Medivation's eight member board of directors in an attempt to gain control of the US firm - and its prize prostate cancer therapy, Xtandi ... Medivation's advanced castration-resistant prostate cancer blockbuster

Deal Watch May 2016

Deal Watch May 2016 The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already

Deal Watch March 2016

Deal Watch March 2016 Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics